BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women- It's been 20 years since MTV's golden couple split. These producers saw it all unravel.
- Image of foreigners being arrested in S.Africa during Eid is AI-generated
- Craig the beer-ambassador elephant dies aged 54
- Fire Allegedly Triggered by Wedding Cake Sparkler Causes Venue to Go Up in Flames, Leaving Groom with Second-Degree Burns
- You finally got a doctor's appointment. Here's how to get the most out of it
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Germany's Pistorius: NATO protects Europe from Iranian missiles
- My daughter is in the #1 movie in the country. She still has to finish her math homework.
